PGT-A/PGT-SR/PGT-M is a laboratory procedure that utilizes molecular techniques to determine the number of chromosomes per embryo. It aims to identify abnormalities in chromosome count, such as Down Syndrome, which may result in reduced pregnancy rates, higher miscarriage risks, and potential genetic disorders in offspring.
Preimplantation Genetic Screening (PGT-A/PGT-SR/PGT-M) focuses on assessing the number of chromosomes in embryos to identify potential implantation failure, miscarriage risks, or syndromes like Trisomy 21. Preimplantation Genetic Diagnosis, on the other hand, targets disease-causing mutations such as Cystic Fibrosis, Huntington’s Disease, and Tay-Sachs. Progenesis employs advanced genome sequencing technologies to identify undesired mutations in embryos, working closely with your IVF doctor to select healthy embryos for transfer.
Preimplantation Genetic Screening (PGT-A/PGT-SR/PGT-M) offers various platforms, including FISH (fluorescence in situ hybridization), aCGH (array comparative genome hybridization), and NGS (Next Generation Sequencing). FISH employs fluorescent labels to evaluate specific regions on a limited number of chromosomes, while aCGH utilizes fluorescence detection on a larger scale. NGS, the latest technology, reads the DNA sequence to directly identify chromosome presence or absence, delivering high-resolution results with reduced chances of false positives or negatives.
You have the option to cancel your PGT-A/PGT-SR/PGT-M test order at any time. However, if the samples have already been processed, sample processing fees may be applicable. Regular pricing will be charged once the samples have been fully processed and the report has been generated.
Progenesis prioritizes the privacy of your information. We are fully compliant with HIPAA regulations, ensuring the protection of patient data. Patient information is not shared with any third party. Test results are directly submitted to your doctor’s office through a secure, HIPAA-compliant protocol as required by law.